SUMO‑specific protease 2 (SENP2) functions as a tumor suppressor in osteosarcoma via SOX9 degradation

Pei,Hong; Chen,Liang; Liao,Quan‑Ming; Wang,Ke‑Jun; Chen,Shun‑Guang; Liu,Zheng‑Jie; Zhang,Zhi‑Cai

doi:10.3892/etm.2018.6838

SUMO‑specific protease 2 (SENP2) functions as a tumor suppressor in osteosarcoma via SOX9 degradation

Authors:
- Hong Pei
- Liang Chen
- Quan‑Ming Liao
- Ke‑Jun Wang
- Shun‑Guang Chen
- Zheng‑Jie Liu
- Zhi‑Cai Zhang
View Affiliations

Affiliations: Department of Orthopaedics, Jing Zhou Central Hospital, The Second Clinical Medical College, Yangtze University, Jingzhou, Hubei 434020, P.R. China, Department of Orthopaedics, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430022, P.R. China
Published online on: October 9, 2018 https://doi.org/10.3892/etm.2018.6838
Pages: 5359-5365

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Osteosarcoma (OS) is the most common primary bone malignancy in children and adolescents, the pathogenesis of which remain largely unknown. Small ubiquitin‑like modifier (SUMO)‑Specific Protease 2 (SENP2) has been reported to serve as a tumor suppressor in hepatocellular carcinoma cells. The aim of the present study was to investigate the critical role of SENP2 in OS cells. Using reverse transcription‑quantitative polymerase chain reaction and western blot assays, it was observed that SENP2 was significantly downregulated in clinical OS tissues compared with adjacent normal samples. Ectopic expression of SENP2 resulted in the suppression of proliferation, migration and invasion in OS cells, whereas SENP2 knockdown by CRISPR‑Cas9‑based gene editing had the opposite effect. SENP2 is associated with the proteasome‑dependent ubiquitination and degradation of SRY‑box‑9 (SOX9). SOX9 silencing impaired SENP2‑depletion‑induced accelerated cell growth and migration. Together, these results suggest that SOX9 is a critical downstream effector of the tumor suppressor SENP2 in OS.

View Figures

View References

1	Jackson TM, Bittman M and Granowetter L: Pediatric malignant bone tumors: A review and update on current challenges, and emerging drug targets. Curr Probl Pediatr Adolesc Health Care. 46:213–228. 2016. View Article : Google Scholar : PubMed/NCBI
2	Ballatori SE and Hinds PW: Osteosarcoma: Prognosis plateau warrants retinoblastoma pathway targeted therapy. Signal Transduct Target Ther. 1:160012016. View Article : Google Scholar : PubMed/NCBI
3	Botter SM, Neri D and Fuchs B: Recent advances in osteosarcoma. Curr Opin Pharmacol. 16:15–23. 2014. View Article : Google Scholar : PubMed/NCBI
4	Hattinger CM, Fanelli M, Tavanti E, Vella S, Ferrari S, Picci P and Serra M: Advances in emerging drugs for osteosarcoma. Expert Opin Emerg Drugs. 20:495–514. 2015. View Article : Google Scholar : PubMed/NCBI
5	Seeler JS and Dejean A: SUMO and the robustness of cancer. Nat Rev Cancer. 17:184–197. 2017. View Article : Google Scholar : PubMed/NCBI
6	David R: Sumoylation: Targeting SUMO. Nat Rev Mol Cell Biol. 11:3872010. View Article : Google Scholar : PubMed/NCBI
7	Li XC, Zeng Y, Sun RR, Liu M, Chen S and Zhang PY: SUMOylation in cardiac disorders-a review. Eur Rev Med Pharmacol Sci. 21:1583–1587. 2017.PubMed/NCBI
8	Guo C and Henley JM: Wrestling with stress: Roles of protein SUMOylation and deSUMOylation in cell stress response. IUBMB Life. 66:71–77. 2014. View Article : Google Scholar : PubMed/NCBI
9	Bawa-Khalfe T and Yeh ET: SUMO losing balance: SUMO proteases disrupt SUMO homeostasis to facilitate cancer development and progression. Genes Cancer. 1:748–752. 2010. View Article : Google Scholar : PubMed/NCBI
10	Kim JH and Baek SH: Emerging roles of desumoylating enzymes. Biochim Biophys Acta. 1792:155–162. 2009. View Article : Google Scholar : PubMed/NCBI
11	Wang K and Zhang XC: Inhibition of SENP5 suppresses cell growth and promotes apoptosis in osteosarcoma cells. Exp Ther Med. 7:1691–1695. 2014. View Article : Google Scholar : PubMed/NCBI
12	Mikolajczyk J, Drag M, Békés M, Cao JT, Ronai Z and Salvesen GS: Small ubiquitin-related modifier (SUMO)-specific proteases: Profiling the specificities and activities of human SENPs. J Biol Chem. 282:26217–26224. 2007. View Article : Google Scholar : PubMed/NCBI
13	Chiu SY, Asai N, Costantini F and Hsu W: SUMO-specific protease 2 is essential for modulating p53-Mdm2 in development of trophoblast stem cell niches and lineages. PLoS Biol. 6:e3102008. View Article : Google Scholar : PubMed/NCBI
14	Shen HJ, Zhu HY, Yang C and Ji F: SENP2 regulates hepatocellular carcinoma cell growth by modulating the stability of β-catenin. Asian Pac J Cancer Prev. 13:3583–3587. 2012. View Article : Google Scholar : PubMed/NCBI
15	Jiang QF, Tian YW, Shen Q, Xue HZ and Li K: SENP2 regulated the stability of β-catenin through WWOX in hepatocellular carcinoma cell. Tumour Biol. 35:9677–9682. 2014. View Article : Google Scholar : PubMed/NCBI
16	Chen L, Pei H, Lu SJ, Liu ZJ, Yan L, Zhao XM, Hu B and Lu HG: SPOP suppresses osteosarcoma invasion via PI3K/AKT/NF-κB signaling pathway. Eur Rev Med Pharmacol Sci. 22:609–615. 2018.PubMed/NCBI
17	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
18	Jo A, Denduluri S, Zhang B, Wang Z, Yin L, Yan Z, Kang R, Shi LL, Mok J, Lee MJ and Haydon RC: The versatile functions of Sox9 in development, stem cells, and human diseases. Genes Dis. 1:149–161. 2014. View Article : Google Scholar : PubMed/NCBI
19	Liu H, Chen Y, Zhou F, Jie L, Pu L, Ju J, Li F, Dai Z, Wang X and Zhou S: Sox9 regulates hyperexpression of Wnt1 and Fzd1 in human osteosarcoma tissues and cells. Int J Clin Exp Pathol. 7:4795–4805. 2014.PubMed/NCBI
20	Gill G: SUMO changes Sox for developmental diversity. Mol Cell. 20:495–496. 2005. View Article : Google Scholar : PubMed/NCBI
21	Hattori T, Kishino T, Stephen S, Eberspaecher H, Maki S, Takigawa M, de Crombrugghe B and Yasuda H: E6-AP/UBE3A protein acts as a ubiquitin ligase toward SOX9 protein. J Biol Chem. 288:35138–35148. 2013. View Article : Google Scholar : PubMed/NCBI
22	Oh HJ, Kido T and Lau YF: PIAS1 interacts with and represses SOX9 transactivation activity. Mol Reprod Dev. 74:1446–1455. 2007. View Article : Google Scholar : PubMed/NCBI
23	Lefebvre V and Dvir-Ginzberg M: SOX9 and the many facets of its regulation in the chondrocyte lineage. Connect Tissue Res. 58:2–14. 2017. View Article : Google Scholar : PubMed/NCBI
24	Tan MY, Mu XY, Liu B, Wang Y, Bao ED, Qiu JX and Fan Y: SUMO-specific protease 2 suppresses cell migration and invasion through inhibiting the expression of MMP13 in bladder cancer cells. Cell Physiol Biochem. 32:542–548. 2013. View Article : Google Scholar : PubMed/NCBI
25	Hu XY, Liu Z, Zhang KL, Feng J, Liu XF, Wang LY and Wang ZW: SUMO-specific protease 2-mediated deSUMOylation is required for NDRG2 stabilization in gastric cancer cells. Cancer Biomark. 21:195–201. 2017. View Article : Google Scholar : PubMed/NCBI
26	Tan M, Zhang D, Zhang E, Xu D, Liu Z, Qiu J, Fan Y and Shen B: SENP2 suppresses epithelial-mesenchymal transition of bladder cancer cells through deSUMOylation of TGF-βRI. Mol Carcinog. 56:2332–2341. 2017. View Article : Google Scholar : PubMed/NCBI